Skip to main content

Table 3 Outcome results of 5 different endpoints for all female cases with primary, non-metastatic, unilateral breast cancer treated at the Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012, (for whom all necessary histological information were available for distinct subtype attribution), differentiated by the invasive clinico-pathological tumor subtype or in-situ tumor (CIS). Results in percent at 5 years (95 % CI)

From: Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

 INVASIVE CANCERCIS
LumA-likeLumB/HER2 neg.-likeLumB/HER2 pos.-likeHER2-typeTriple negative
n = 3454 (100 %) [missing due failed distinct subtype distribution n = 149, i.e. 4.1 % of invasive cohort]n = 499 (100 %)
n = 1545n = 1099n = 215n = 171n = 424 
44.7 %31.8 %6.2 %5.0 %12.3 % 
LCR [%] (95 % CI)99.1 (98.5; 99.7)95.2 (93.6; 96.8)95.0 (91.3; 98.7)90.5 (84.7; 96.3)89.6 (85.8; 93.4)96.2 (93.9; 98.5)
DFS [%] (95 % CI)92.2 (90.5; 93.9)80.1 (77.2; 83.0)79.0 (71.9; 86.1)77.0 (69.4; 84.6)69.1 (64.1; 74.1)93.0 (90.2; 95.8)
DDFS [%] (95 % CI)92.9 (91.3; 94.5)82.2 (79.5; 84.9)82.8 (76.0; 89.6)83.3 (76.6; 90.0)72.2 (67.3; 77.1)95.6 (93.5; 97.1)
OS [%] (95 % CI)95.1 (93.7; 96.5)88.7 (86.2; 91.2)92.5 (87.9; 97.1)85.6 (78.6; 92.6)78.5 (73.8; 83.2)96.9 (94.8; 99.0)
ROS [%] (95 % CI)100.0 (98.5; 101.5)93.4 (90.7; 96.1)96.0 (91.2; 100.8)88.8 (81.5; 96.1)80.1 (75.1; 85.1)100.8 (98.6; 103.0)
  1. CI confidence interval, LCR local recurrence rate, DFS disease-free survival, DDFS distant disease-free survival, OS observed overall survival, ROS relative overall survival, CIS carcinoma-in-situ